The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
Does receptor balance matter?comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models
Gentili A, Failla G, Melnyk A, Puleo V, Tanna GLD, Ricciardi W, et al
REMEVi's tirzepatide is $249 for the first month, then $379/month ($269/month on the 52-week plan) lower than Eden's ongoing rate of approximately $329/month